Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy

作者：Michael Atkins, David H. McDermott, Meredith M. Regan, E J Stanbridge, Melissa P. Upton, Amanda Youmans, Philip G. Febbo, Mirna Lechpammer, Sabina Signoretti · 发表于：Journal of Clinical Oncology · 年份：2004 · DOI：10.1200/jco.2004.22.90140.4512 · 被引用次数：12 · 研究领域：Enzyme function and inhibition、Renal cell carcinoma treatment、Peptidase Inhibition and Analysis

4512 Background: RCC response to IL-2 Rx and patient (pt) survival have been correlated to histology including the presence of clear cell and alveolar and the absence of papillary and granular features (Upton et al Proc ASCO, 2003) and CAIX expression (Bui et al Clin Ca Res 2003;9:802). In an effort to confirm and expand these findings we undertook a nested case-control study within the Upton cohort. Methods: Paraffin-embedded tissue sections of RCC were immunostained with an Ab to CAIX and expression levels were correlated with pathology findings, clinical outcome and the Upton model relating them. The percentage of CAIX positive tumor cells was utilized to separate high (> 85%) vs low (≤ 85%) expressers. Results: Tissue specimens were obtained from 66 pts (51M, 15F). 27 of the selected pts (41%) had responded (10CR/17PR) to IL-2. 24 (36%), 31 (47%) and 11 (17%) were classified as good, intermediate, and poor prognosis according to the Upton model. 41 specimens (62%) had high CAIX expression. 21 of 27 (78%) responding pts had high CAIX expression compared to 20/39 (51%) non-responders (OR=3.3; p=0.04); a similar survival benefit was seen (p=0.04). Survival >5 yrs was seen only in high CAIX expressors. High CAIX staining was associated with better pathology prognosis, and when stratified by group, the ORs of CAIX expression were unequal across groups (p=0.08) . The stongest association was in the intermediate group where 9/9 responders has high CAIX expression vs.11/22 non-re...